The New England Journal of Medicine: Roentgenologic Demonstration of Renal Papillary Necrosis in Sickle-Cell Trait
This page lists all known medications that could potentially lead to 'Renal papillary necrosis' as a side effect. It's important to note that mild side effects are quite common with medications. The ...
Renal & Urology News: Cytoreductive Nephrectomy May Up Survival in Papillary mRCC
5-cyroreductive-nephrectomy-0516 Study reveals a 38% decreased risk of death in patients with papillary metastatic renal cell carcinoma who undergo cytoreductive nephrectomy vs those who do not. The ...
Major consensus conferences held over a decade ago laid the foundations for the current (2004) WHO classification of renal carcinoma. Clear cell, papillary and chromophobe carcinomas account for 85–90 ...
EurekAlert!: CALYPSO: combined MET and PD-L1 inhibition shows promise in a cohort of patients with MET-driven metastatic papillary renal cancer.
Metastatic papillary renal cancer has a poor prognosis with few treatment options available. Based on preclinical data suggesting positive interaction between MET and PD-L1 inhibition, the CALYPSO ...
CALYPSO: combined MET and PD-L1 inhibition shows promise in a cohort of patients with MET-driven metastatic papillary renal cancer.
Dialysis, also called comprehensive renal replacement therapy, is a life-sustaining procedure for people with kidney failure. Mayo Clinic Health System specializes in dialysis services, and we are nationally recognized for high-quality patient care. Your kidneys remove waste products and excess fluid from the blood. When your kidneys stop working, dialysis works in their place. It filters your ...
The New England Journal of Medicine: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer